Steven-Johnson Syndrome and Toxic Epidermal Necrolysis in a Patient Treated With Cabozantinib: A Case Report of a Fatal Adverse Reaction.

Authors

Alberto Zambudio-Munuera, Miguel Herráez-Marcos, Miguel Angel Arrabal-Polo, Francisco Gutiérrez-Tejero, Miguel Arrabal-Martín

Published in

Asia-Pacific journal of clinical oncology. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

Cabozantinib is a multikinase inhibitor with high efficacy in patients with metastatic renal cell carcinoma. We present the case of a 53-year-old patient undergoing second-line treatment for metastatic renal cell carcinoma who presented with extensive skin lesions consistent with Stevens-Johnson syndrome, confirmed by biopsy. He presented a torpid course, progressing to toxic epidermal necrolysis and subsequent death despite supportive measures and immunoglobulin treatment. Although cabozantinib can cause skin reactions, such torpid and aggressive reactions as those observed in this clinical case have not been reported.

PMID:
42629957
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.